Literature DB >> 10890504

Toxicity of the heterocyclic amine batracylin: investigation of rodent N-acetyltransferase activity and potential contribution of cytochrome P450 3A.

G J Stevens1, J L Burkey, C A McQueen.   

Abstract

The heterocyclic amine, batracylin (BAT), is genotoxic and several lines of evidence suggest that acetylation is one step in the formation of a DNA-damaging product. The variation in susceptibility to BAT toxicity observed between rats and mice has also been linked to the acetylated product. BAT N-acetyltransferase (NAT) activity was determined in rat and mouse hepatic cytosols. Formation of acetylbatracylin (ABAT) was 6 times greater in F-344 hepatic samples compared to either mouse strain, while hepatic BAT NAT activities were similar in C57B1/6 and A/J mice. No deacetylation of ABAT was detected. In contrast, 2-aminofluorene NAT activity in C57B1/6 hepatic cytosol was twice that of the A/J strain and activities in both strains of mice were greater than in rat. Deacetylation of 2-acetylaminofluorene was detected in both species with enzyme activities in C57B1/6>A/J>F-344. Hepatocytes from the F-344 rats, the species most sensitive to BAT toxicity, were used to investigate the contribution of other biotransformation reactions to BAT cytotoxicity. Leakage of cellular lactate dehydrogenase was greater in hepatocytes from male rats than from females, increased on in vivo exposure to dexamethasone, and decreased in the presence of troleandomycin, suggesting that CYP3A-mediated biotransformation of BAT is involved in the formation of a cytotoxic product. When phenol red, a substrate for UDP-glucuronsyltransferase (UDPGT), was absent from the medium, BAT cytotoxicity was reduced. These data are consistent with a role for NAT, CYP, and UDPGT in the biotransformation of BAT.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10890504     DOI: 10.1023/a:1007692503817

Source DB:  PubMed          Journal:  Cell Biol Toxicol        ISSN: 0742-2091            Impact factor:   6.691


  3 in total

1.  Characterization of Batracylin-induced Renal and Bladder Toxicity in Rats.

Authors:  Myrtle Davis; Deborah I Bunin; Steven J Samuelsson; Kenneth P Altera; Robert J Kinders; Scott M Lawrence; Jiuping Ji; Matthew M Ames; Sarah A Buhrow; Chad Walden; Joel M Reid; Linda L Rausch; Toufan Parman
Journal:  Toxicol Pathol       Date:  2014-10-01       Impact factor: 1.902

2.  Comparative Metabolism of Batracylin (NSC 320846) and N-acetylbatracylin (NSC 611001) Using Human, Dog, and Rat Preparations In Vitro.

Authors:  Joseph M Covey; Joel M Reid; Sarah A Buhrow; Mary Kuffel; Chad Walden; Holger Behrsing; Matthew M Ames
Journal:  J Drug Metab Toxicol       Date:  2016-05-08

3.  Pharmacogenetically driven patient selection for a first-in-human phase I trial of batracylin in patients with advanced solid tumors and lymphomas.

Authors:  Shivaani Kummar; Martin E Gutierrez; Lawrence W Anderson; Raymond W Klecker; Alice Chen; Anthony J Murgo; James H Doroshow; Jerry M Collins
Journal:  Cancer Chemother Pharmacol       Date:  2013-08-03       Impact factor: 3.333

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.